Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-894 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-894 | DRUG | Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks. |
| atomoxetine | DRUG | Subjects will take 40 mg BID or placebo for up to four weeks. |
| placebo | DRUG | Subjects will take BID for up to four weeks |
Inclusion Criteria: * Meet criteria for attention-deficit/hyperactivity disorder * Have voluntarily signed an informed form * Are between 18 and 60 years of age * Will use contraceptive methods during the study * Women must not be pregnant or breast-feeding * Must be in generally good health * Are ...
ABT-894 is an investigational small molecule being studied for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
ABT-894 is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. The drug is currently in Phase 2 clinical trials for adult ADHD.
ABT-894 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. One Phase 2 trial has been completed, and the drug remains under investigation for adult ADHD.
ABT-894 has one completed Phase 2 clinical trial, identified as NCT00429091. This was a dose-ranging study evaluating the efficacy of ABT-894 in adults with Attention-Deficit/Hyperactivity Disorder. The trial enrolled 243 participants in the United States and was randomized, double-blind, and placebo-controlled.
No alternative names for ABT-894 have been disclosed. The drug is identified solely by its code name ABT-894 in clinical trial records and is being developed by Abbott Laboratories for adult ADHD.